OptiMedica Corp., a Sunnyvale, Calif.-based global ophthalmic device company, has closed a $35m growth round of financing.
Backers include existing investors Kleiner Perkins Caufield & Byers, Alloy Ventures, DAG Ventures, BlackRock Private Equity Partners and Bio*One Capital.
The company intends to use the funding for the global commercialization of its Catalys® Precision Laser System for cataract surgery, development of innovative enhancements, and advancement of a portfolio of additional products.
Founded in 2004 and led by Mark J. Forchette, president and chief executive officer, OptiMedica has developed Catalys, which is U.S. FDA market cleared and CE mark approved for performing every step of the laser cataract procedure. Launched in November 2011, the system has been installed at ophthalmic practices in 10 countries and used to perform more than 6,000 laser cataract procedures worldwide.
FinSMEs
16/11/2012